The Michael J. Fox Foundationís Partnering Program is designed to proactively showcase promising research results in the Foundationís portfolio for funders who want to invest in their continued development. By promoting collaboration between our awardees and industry groups, the Foundation aims to propel forward promising projects in Parkinsonís disease research along the drug development pipeline.
The Partnering Program formalizes the process of developing direct, proactive relationships with industry, including advising companies about potential collaborative opportunities. It encourages select awardees to submit public overviews highlighting their organization, team and projects. These overviews will then be made available for review by industry groups. Awardees spanning the Parkinsonís disease drug development pipeline, from basic to clinical research, and from academia and industry alike, will be showcased through this initiative.
Selected for the MJFF Partnering Program 2H 2013 are:
Eboo Pharmaceutical Inc. is developing a unique series of compounds with the potential to alleviate PD symptoms and mitigate the motor complications (dyskinesia) related to dopamine replacement therapy.
FPRT Bio Inc. is studying XPro1595, which ďturns offĒ inflammation to stop the loss of dopaminergic neurons and prevent disease progression.
MentiNova Inc. is repurposing a compound developed for pain management for the treatment of levodopa-induced dyskinesia and other hyperkinetic movement disorders.
View all Participants of the Partnering Program
Curious to learn more about the Program?